Tuesday, November 21, 2017

EyewireTV — OIS Coverage Part 1: Ophthalmic Devices

In this week’s EyewireTV, executives of device companies at the Ophthalmology Innovation Summit in New Orleans provide EyewireTV updates on their company’s products and pipeline.

Watch Video

Wednesday, November 15, 2017| Carl Zeiss Meditec, Cataract Surgery, Dry Eye, EnFocus Ultra-HD OCT Technology, Leica Microsystems, Leica Proveo 8 Microscope, Microscopes, Product Releases, Tear Film, Visiometrics

EyewireTV — Breaking News Live from the AAO Meeting in New Orleans

In this week’s EyewireTV, Zeiss unveils its VERACITY Surgical system, an intuitive cloud-based platform for cataract surgery planning, logistics, treatment, risk management, and analysis; and Leica Microsystems debuts the EnFocus Intrasurgical OCT system, used in combination with its Proveo 8 microscope platform. Also, Visiometrics introduces its Tear Film Analyzer, a fast, objective, and noninvasive way to measure vision fluctuation caused by dry eye disease.

Watch Video

Tuesday, November 07, 2017| Bausch+Lomb, FDA Approval/Clearance, Glaucoma, Hydrus™ Microstent, Ivantis, Nicox

EyewireTV - New Glaucoma Treatment Approved; PMA for Hydrus Microstent

In this week’s EyewireTV, Bausch + Lomb and Nicox receive FDA approval for glaucoma treatment Vyzulta (latanoprostene bunod 0.024%), and Ivantis submits its final premarket approval submission to the FDA for the Hydrus Microstent MIGS device.

Watch Video

Wednesday, November 01, 2017| Alcon, Alcon, EyeQue, FDA Approval/Clearance, Inflammation, Kala Pharmaceuticals, Novartis, Visual Acuity

EyewireTV — Novartis Delays Alcon Decision; Kala Drug Candidate NDA

In this week’s EyewireTV, amid signs of a turnaround, Novartis delays a possible spinoff of Alcon until the first half of 2019; and Kala Pharmaceuticals submits a new drug application to the FDA for its postoperative ocular inflammation and pain treatment candidate Inveltys (KPI-121 1%). Also, EyeQue launches the EyeQue Insight visual acuity screener, a device that tests clarity of distance vision and tracks vision changes over time.

Watch Video

Wednesday, October 25, 2017| Bausch+Lomb, Dry Eye, enVista, FDA Approval/Clearance, Hydrophobic acrylic IOLs, Imprimis Pharmaceuticals, VICTUS Femtosecond Laser

EyewireTV — Compounded Cyclosporine Introduced; Victus Upgrades

In this week’s EyewireTV, Imprimis Pharmaceuticals is releasing compounded cyclosporine-based formulations for the treatment of dry eye disease, and forming a subsidiary called Surface Pharmaceuticals to advance treatments for ocular surface diseases; and Bausch + Lomb receives FDA 510(k) clearance for software and hardware upgrades for the Victus femtosecond laser. Also, Bausch + Lomb introduces the enVista MX60E IOL, the company's next-generation hydrophobic acrylic lens.

Watch Video

Wednesday, October 18, 2017| Aerie Pharmaceuticals, cellular or cell-based therapy, FDA Approval/Clearance, Gene Therapy, Glaucoma, inherited retinal diseases (IRDs), Spark Therapeutics, Topcon Medical Systems

EyewireTV — Aerie and Spark Receive Positive FDA Committee Votes; New PASCAL Laser Cleared

In this week’s EyewireTV, Aerie Pharmaceuticals receives a favorable vote from the FDA’s Dermatologic and Ophthalmic Drugs advisory committee for glaucoma treatment candidate Rhopressa (netarsudil ophthalmic solution 0.02%); and Spark Therapeutics receives a unanimous recommendation from the FDA's Cellular, Tissue, and Gene Therapies advisory committee for its gene therapy Luxturna (voretigene neparvovec) for use in patients with vision loss due to confirmed biallelic RPE65-mediated inherited retinal disease. Also, Topcon Medical Systems announces that its PASCAL Synthesis TwinStar laser has received FDA 510(k) clearance.

Watch Video
Load More